Protocols
Curated research protocols for top peptides. Each entry includes dose, frequency, cycle length, reconstitution, and storage.
Protocol
~6 hours
Standard research dose for BPC-157 is 250-500 mcg under the skin (s.c. injection) daily for 4-6 weeks. Local injection (near the target tissue) shows higher tissue concentration than systemic dosing (Sikiric, 2018). Half-life ~6 hours.
See protocolProtocol
2-3 days
Standard research dose for TB-500 is 2-2.5 mg under the skin (s.c. injection) 2× weekly for 4-6 weeks (loading), followed by 2-2.5 mg weekly maintenance. Half-life significantly longer than BPC-157 — hence less frequent dosing.
See protocolProtocol
Short systemic (minutes); local retention longer
GHK-Cu in research protocols is applied topically (0.05-0.2% in cream/serum) or systemically under the skin (s.c. injection) 1-2 mg daily for 4-8 weeks. Systemic protocols are less studied than topical.
See protocolProtocol
Short systemic; gastric-stable
KPV is administered under the skin (s.c. injection) at 200-500 mcg daily for 4-6 weeks. Due to its small molecular mass it is gastric-stable — also studied in oral form for gut conditions.
See protocolProtocol
~7 days
Semaglutide (GLP-1, hormone that reduces appetite) titrates slowly: 0.25 mg under the skin (s.c. injection) weekly for 4 weeks, 0.5 mg for next 4, then increase to 1.0-2.4 mg weekly. STEP protocols test up to 2.4 mg — mean 14.9% weight loss over 68 weeks.
See protocolProtocol
~5 days
Tirzepatide (dual agonist of GLP-1, hormone that reduces appetite, and GIP, hormone that improves insulin sensitivity) starts at 2.5 mg under the skin (s.c. injection) weekly for 4 weeks, then increases by 2.5 mg every 4 weeks up to target 5-15 mg. SURMOUNT-1 shows 22.5% weight loss over 72 weeks at 15 mg.
See protocolProtocol
~6 days
Retatrutide (triple agonist of GLP-1, hormone that reduces appetite, GIP, hormone that improves insulin sensitivity, and glucagon; Phase 3) titrates from 2 mg under the skin (s.c. injection) weekly, increasing by 2 mg every 4 weeks to target 8-12 mg. Phase 2 NEJM 2023 shows 24.2% weight loss over 48 weeks at 12 mg.
See protocolProtocol
~2 hours
Standard Ipamorelin dose is 200-300 mcg under the skin (s.c. injection) 2-3× daily (pre-breakfast, pre-workout, pre-bed). Frequently stacked with CJC-1295 for a dual growth-hormone pulse. Cycles run 8-12 weeks with a 4-week off period.
See protocolProtocol
~30 min (no DAC); 6-8 days (with DAC)
CJC-1295 (no DAC) is dosed at 100 mcg under the skin (s.c. injection) 2-3× daily alongside a GHRP (growth-hormone-releasing peptide) like Ipamorelin. Short half-life (~30 min) mimics natural pulsatility. DAC version is dosed 1-2× weekly.
See protocolProtocol
~26 minutes
Tesamorelin (FDA-approved) is dosed at 2 mg under the skin (s.c. injection) daily. Selective visceral fat (around the organs) reduction — 15-18% over 26 weeks in HIV lipodystrophy (Falutz, NEJM 2007). Does not affect subcutaneous fat.
See protocolProtocol
~2.7 hours
PT-141 (FDA-approved Vyleesi) is dosed at 1.75 mg under the skin (s.c. injection) as needed, 45 minutes before anticipated effect. Not more than 8 doses per month. Acts centrally on the hypothalamus (MC4R) — unlike peripheral vasodilators (vessel dilators).
See protocolProtocol
Complex metabolism; ~10 minutes serum
NAD+ is administered under the skin (s.c. injection) or intravenously (into the vein). Subcutaneous protocols: 50-100 mg daily for 1-2 weeks loading, then 100-200 mg 2-3× weekly maintenance. IV infusions: 250-1000 mg over 2-4 hours.
See protocol